Biologics and Biosimilars: Regulatory Aspects Certificate
The Certificate in Biologics and Biosimilars: Regulatory Aspects in the School of Pharmacy at Temple University helps students gain the knowledge and credentials needed to work in the U.S and global regulations governing biologics and biosimilar drugs. This certificate is part of the School of Pharmacy’s regulatory affairs (RA) and quality assurance (QA) graduate program.
The Biologics and Biosimilars: Regulatory Aspects Certificate explores the following topics.
- Regulatory issues that are unique to biologics and biosimilar drug manufacturers
- The current regulatory and technical/scientific issues involved in developing biological products in major International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) regions
- The clinical, manufacturing, regulatory and strategic issues that challenge the path to global commercialization of a biological product
- The principles that guide the development of biosimilar drugs
- How biosimilar development differs from innovator drug development
- How biologics and biosimilars differ from chemically synthesized drugs
- The analytical methods used to characterize biologics and how analytical testing differs from small molecule testing
- The quality by design principles related to the development, manufacturing and testing of biologics
This specialized curriculum delves into the requirements of major ICH markets for biologics and biosimilar products. The certificate builds a strong foundation in the biologics and biosimilar regulatory landscape. Through the courses, students are exposed to key trends and controversies facing the biologics and biosimilar industry.
The Certificate in Biologics and Biosimilars: Regulatory Aspects enables students to sharpen their knowledge of this industry niche without committing to the entire master’s degree. This certificate provides the tools and information to understand how biologics and biosimilars are regulated nationally, regionally and globally.
Executive recruiters often call Temple’s RA and QA office seeking candidates with demonstrated knowledge of the regulations governing this discipline. The Certificate in Biologics and Biosimilars: Regulatory Aspects provides students with credentials from Temple’s well-respected RA and QA graduate program, giving them a solid grounding in key U.S. and global regulations that affect biologic and biosimilar products. The certificate is open to both MS in RA and QA applicants and MS graduates, who can expand their career opportunities with this new credential.
Learning Objectives
Upon completion of the Certificate in Biologics and Biosimilars: Regulatory Aspects, students will better understand the following.
-
U.S. and global regulatory landscape for biologics and biosimilars
-
The differences between biologics and small molecules
-
The complexities and challenges in drug development across disciplines, e.g., toxicology; clinical; and chemistry, manufacturing and controls (CMC)
-
The strategy for preclinical and clinical studies as applied to biologics and biosimilar products
-
The basics of biologics and biosimilar CMC strategies
Post-master’s Certificate
Students have the option to complete a post-master’s curriculum in biologics and biosimilars: regulatory aspects. This post-master’s certificate explores the regulatory, strategic, technical and scientific issues that are unique to biologics and biosimilar drug manufacturers. To apply for this 15-credit program, applicants must hold a master’s degree in a pharmacy-related field and a bachelor of science degree in biology, chemistry, engineering, pharmacy, physics or related fields.
Learn more about the Post-master’s Certificate in Biologics and Biosimilars: Regulatory Aspects.